Peminib 13.5 mg is an oral precision therapy drug with Pemigatinib, used for cholangiocarcinoma, a rare, aggressive bile duct cancer. Pemigatinib is a selective inhibitor of the FGFR family of receptors, most notably FGFR1, FGFR2, and FGFR3. Pemigatinib is for use in adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement as identified by an FDA-approved test.

Pemigatinib blocks the activity of FGFR proteins, which are critical for cell survival and growth. Abnormal fusions of the FGFR2 gene in some cancer types, such as cholangiocarcinoma, can trigger tumor growth. By blocking these signals, Pemigatinib disrupts the cancer's growth and development, offering a targeted treatment that might yield improved outcomes for patients with limited other treatment options.

Peminib 13.5 mg is indicated for:

Adults with unresectable or metastatic FGFR2 fusion-positive cholangiocarcinoma

Adults who have already received one or more lines of systemic therapy

Only in patients with documented FGFR2 alterations, as evidenced by molecular diagnostic testing, should this drug be given.

In a 21-day cycle, the recommended dosage is 13.5 mg taken orally once daily for 14 days in a row, with 7 days off from therapy.

 It is recommended to take tablets whole, either with or without food.

Dose adjustment can be performed based on patient tolerance, liver function, or side effect profile.

Common side effects of Peminib are as follows:

Hyperphosphatemia (increased phosphate)

Alopecia (hair loss)

Diarrhea

Fatigue

Nausea

Stomatitis (mouth ulcers)

Dry eyes or blurred vision

Retinal detachment, electrolyte abnormalities, and hyperphosphatemia that causes soft tissue calcification are serious side effects. Regular monitoring should be done during treatment.

Eye Examination: Regular ophthalmologic examination is required in patients due to the potential risk of retinal abnormality.

Phosphate Monitoring: Serum phosphate monitoring must be done and managed appropriately.

Reproductive Risk: Pemigatinib will cause fetal harm. Appropriate contraception must be used during therapy and for some duration after the last dose.

Drug Interactions: Simultaneous administration with strong CYP3A inducers or inhibitors may affect Pemigatinib levels.

Store Peminib tablets in a dry, cool place (room temperature, 20° to 25°C or 68°F to 77°F), away from direct sunlight and moisture. Keep out of reach of children.

The information given here is for educational and informative purposes only and is not a substitute for medical advice. Always consult your oncologist or healthcare provider for guidance before starting any new drug.

Peminib 13.5 mg (Pemigatinib) is a significant advancement in the targeted treatment of FGFR2-altered cholangiocarcinoma. In offering an individualized treatment solution for cancer, it brings hope anew to cancer patients with this virulent and uncommon disease.